387 related articles for article (PubMed ID: 33721436)
1. Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.
Hacibekiroglu I; Ozkul O; Cakir E; Kostek O; Karatas F; Esenkaya A; Demirci A; Bilir C
J BUON; 2021; 26(1):79-86. PubMed ID: 33721436
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
3. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
von Pawel J; Schiller JH; Shepherd FA; Fields SZ; Kleisbauer JP; Chrysson NG; Stewart DJ; Clark PI; Palmer MC; Depierre A; Carmichael J; Krebs JB; Ross G; Lane SR; Gralla R
J Clin Oncol; 1999 Feb; 17(2):658-67. PubMed ID: 10080612
[TBL] [Abstract][Full Text] [Related]
4. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Song Z; Shao L; Lin B; Zhang Y
Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ; Dvorkin M; Laktionov K; Navarro A; Juan-Vidal O; Kozlov V; Golden G; Jordan O; Deng CQ; Bentsion D; Chouaid C; Dechev H; Dowlati A; Fernández Núñez N; Ivashchuk O; Kiladze I; Kortua T; Leighl N; Luft A; Makharadze T; Min Y; Quantin X;
Lung Cancer; 2022 Apr; 166():135-142. PubMed ID: 35278766
[TBL] [Abstract][Full Text] [Related]
6. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
7. Topotecan: a review of its efficacy in small cell lung cancer.
Ormrod D; Spencer CM
Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
10. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer].
Xing H; Zhang J; Ge F; Yu X; Bian H; Zhang F; Fang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):167-172. PubMed ID: 33819966
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
[TBL] [Abstract][Full Text] [Related]
16. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
Gervais R; Le Caer H; Monnet I; Falchero L; Baize N; Olivero G; Thomas P; Berard H; Auliac JB; Chouaid C;
Clin Lung Cancer; 2015 Mar; 16(2):100-5. PubMed ID: 25467927
[TBL] [Abstract][Full Text] [Related]
17. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Kim SH; Kim MJ; Kim YJ; Chang H; Kim JW; Lee JO; Lee KW; Kim JH; Bang SM; Lee JS
Medicine (Baltimore); 2017 Oct; 96(42):e8176. PubMed ID: 29049199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
